177lu-psma-617 for the early treatment of prostate cancer
Published 3 years ago • 1.6K plays • Length 5:37Download video MP4
Download video MP3
Similar videos
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
1:06
the benefits of 177lu-psma-617 plus olaparib for prostate cancer
-
1:34
lu-psma-617 deployment and future of prostate cancer treatment
-
1:00
is there are role for 177lu-psma-617 in earlier lines of treatment for mcrpc?
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
0:28
177lu-psma-617 for metastatic castration-resistant prostate cancer
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
2:21
final analysis of keynote-585: pembrolizumab and chemotherapy in g/gej cancer
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
0:57
real-world outcomes of 177lu-psma-617 in mcrpc
-
5:06
psmaddition: 177lu-psma-617 plus soc vs. soc alone in metastatic hormone-sensitive prostate cancer
-
5:27
177lu-psma-617 radionuclide therapy in mcrpc
-
4:48
vision: lu-177-psma-617 in mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
0:29
a phase i/ii dose-escalation study of fractionated dose 177lu-psma-617 for progressive mcrpc
-
5:30
fractionated dose 177lu-psma-617 in patients with mcrpc
-
1:28
vision: 177lu-psma-617 in psma-positive mcrpc
-
2:02
the development and results of a dose-intense regimen using 177lu-psma-617 for progressive mcrpc